ReviewJournal of clinical medicine2023
Immunotherapy in Elderly Patients Affected by Non-Small Cell Lung Cancer: A Narrative Review.
Review in Journal of clinical medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- A multicenter, open-label, phase II trial of pemetrexed plus bevacizumab in elderly patients with previously untreated advanced or recurrent nonsquamous non-small cell lung cancer.Thoracic cancer · 2023Trial
- Lobectomy, segmentectomy, and wedge resection for elderly patients with solid-predominant stage I NSCLC: survival, pulmonary function, and postoperative outcomes.Translational lung cancer research · 2026Article
- From real-world pharmacovigilance data to clinical practice: a geriatric-specific predictive model for immune-related adverse events in lung cancer based on routine clinical indicators.BMC geriatrics · 2026Article
- Machine learning-based prediction of 3-month mortality in elderly patients with non-small cell lung cancer and bone metastases.Scientific reports · 2026Article
- Article
- Clinical Outcomes of First-Line Pembrolizumab Monotherapy in Advanced NSCLC With PD-L1 Tumor Proportion Score of 1% to 49%: A Retrospective Multicenter Study.JTO clinical and research reports · 2026Article
- Association of sarcopenia with survival and treatment response in brain metastasis of non-small cell lung cancer.Scientific reports · 2026Article
- Distribution and function of human long-lasting T cells in aging and non-small cell lung cancer.Frontiers in immunology · 2026Review
- A Retrospective Study of First-Line Immunotherapy for Advanced Non-Small Cell Lung Cancer in the Elderly.Aging medicine (Milton (N.S.W)) · 2025Article
- Predictive Value of the Estimated Dose of Radiation to Immune Cells Versus Conventional Parameters in Elderly Patients With Unresectable Stage III NSCLC: A Two-Center Real-World Study.Thoracic cancer · 2025Article
- Survival Outcomes of Immune Checkpoint Inhibitors in Conjunction with Cranial Radiation for Older Adults with Non-Small Cell Lung Cancer and Synchronous Brain Metastasis.Current oncology (Toronto, Ont.) · 2025Article
- Article
- Camrelizumab-based therapies for the treatment of advanced lung cancer: a prospective, open-label, multicenter, observational, real-world study.Frontiers in immunology · 2025Observational
- Effectiveness and Safety of Immune Checkpoint Inhibitors in Older Cancer Patients.Journal of personalized medicine · 2024Article
- Histo-Molecular Factors of Response to Combined Chemotherapy and Immunotherapy in Non-Small Cell Lung Cancers.Targeted oncology · 2023Article
- Surgery for octogenarians: the secret is in the selection.Journal of thoracic disease · 2023Article
- Dysbiosis of the gut microbiome in elderly patients with hepatocellular carcinoma.Scientific reports · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung cancer is the leading cause of cancer-related deaths worldwide. Non-small cell lung cancer (NSCLC) accounts for approximately 80% of all lung cancers, and most NSCLC is diagnosed in the advanced stage. The advent of immune check point inhibitors (ICIs) changed the therapeutic scenario both in metastatic disease (in first and subsequent lines) and earlier settings. Comorbidities, reduced organ function, cognitive deterioration, and social impairment give reasons for a greater probability of adverse events, making the treatment of elderly patients challenging. The reduced toxicity of ICIs compared to standard chemotherapy makes this approach attractive in this population. The effectiveness of ICIs varies according to age, and patients older than 75 years may benefit less than younger patients. This may be related to the so-called immunosenescence, a phenomenon that refers to the reduced activity of immunity with older age. Elders are often under-represented in clinical trials, even if they are a large part of the patients in a clinical practice. In this review, we aim to explore the biological aspects of immunosenescence and to report and analyze the most relevant and recent literature findings on the role of immunotherapy in elderly patients with NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.